Changes in the lymph nodes during the earliest phases of rheumatoid arthritis - Lymph nodes in the earliest phases of rheumatoid arthritis

Academisch Medisch Centrum0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Healthy controls: negative for IgM-RF and anti-CCP antibodies
•Autoantibody-positive individuals: positive for IgM-RF and/or anti-CCP antibodies + either arthralgia or a first degree relative with RA.
•Early arthritis patients: arthritis < 1 year, disease-modifying antirheumatic drug (DMARD) naive + classified as RA according to the 2010 ACR/EULAR criteria for RA or as unclassified arthritis (UA).

•For all individuals:
•- Current/previous use of disease modifying anti-rheumatic drugs (DMARDs).
•- If applicable: patients in whom anticoagulant therapy cannot be temporarily stopped before the procedure
•- Systemic prednisolone use less then 28 days before enrolment
•- Present or previous treatment with any cell depleting therapies, including investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)
•- Presence of any disease for which study subjects need chronic or intermittent immunosuppressive therapy (e.g. prednisolone for COPD).
•- History of chronic viral infection
•- History of autoimmune diseases
•- History of malignancies

发起方